

RESULTS FROM A STATEWIDE SURVEY OF HEALTH CARE PROVIDERS ON HPV VACCINE UTILIZATION



SARA N. COOK, MPH, CHES
CERVICAL CANCER/HPV PROJECT DIRECTOR

California Immunization Coalition Summit April 18, 2011

CMA Foundation Mission

The CMA Foundation champions improved individual and community health through a partnership of leaders in medicine, related health professions, and the community.


Cervical Cancer/HPV Project

- The goal of the project is to educate both patients and clinicians about the connection between the Human Papillomavirus [HPV] and Cervical Cancer with the ultimate aim of promoting strategies that can prevent both Cervical Cancer and HPV.
- As part of a national Cervical Cancer-Free Campaign, our aim is to focus on reducing the prevalence of cervical cancer through increased screening and HPV vaccination.


2010 HPV Vaccine Provider Survey

- Purpose assess utilization of the HPV vaccines among California providers and better understand provider attitudes towards and barriers to HPV vaccination.
- □ <u>Target Audience</u> Health care providers in CA
 - Web-based survey was sent via email or within enewsletters to CA ACOG members, CAPA members, CANP members, community clinic consortia and the California Medical Association distribution lists for family practice physicians, internal medicine physicians and pediatricians.
- Total Respondents 482 health care providers completed the survey.


Survey respondent reported position




Physician reported specialty




Provider reported race/ethnicity




Provider length of practice




Provider reported primary focus of practice




Provider reported setting of practice



Provider reported size of practice




Provider reported area of practice




Patient Population Demographics

Provider responses to the question "Does your practice serve a large proportion of racial/ethnic minority patients?"




Patient Population Demographics

Provider reported primary race/ethnicity of their patient population (could mark all that apply)




Patient Population Demographics


Provider responses to the question "What type of insurance coverage do the majority of your patients have?"




Which of the following vaccines does your practice administer?




What is the most common method your practice is using to ensure that your patients are receiving the HPV vaccine?




How often do you recommend the HPV vaccine to the following groups?



Percentage of providers who report each of the following occurring frequently or sometimes in their primary practices.




Percentage of providers who report each of the following occurring frequently or sometimes in their primary practices.




Attitudes


Percentage of providers who agree with the following statements regarding HPV.




Attitudes – by practice specialty




Cost Barriers




Cost Barriers – by practice specialty



Cost Barriers – by practice specialty




Cost Barriers – by practice specialty




Cost Barriers

Does your practice currently use any of the following mechanisms to overcome financial barriers to HPV vaccination?



Cost Barriers - by practice specialty



Suggestions

- Which of the following options would be helpful in improving provider communication with parents and patients about the HPV vaccine (check all that apply)?
- Educational materials for parents 84%
- 2. Educational materials for teens (ages 13-19) 78%
- 3. Educational materials for young adults (ages 20-26) 70%

Suggestions

- Which of the following topics have you found to be the most important to discuss with patients and parents about the HPV vaccine?
- 1. Basic information on HPV and associated diseases -88%
- 2. Sexual transmission of HPV **76**%
- 3. Who is at risk of HPV -74%
- 4. Vaccine safety **74**%

Acknowledgements

- Heidi M. Bauer, MD, MS, MPH
 Chief, Program Development and Evaluation
 STD Control Branch
 California Department of Public Health
- Gail Sondermeyer
 MPH Candidate
 Infectious Disease & Vaccinology
 UC Berkeley School of Public Health

For More Information

Contact:

Sara N. Cook, MPH, CHES

Cervical Cancer/HPV Project Director

(916) 779-6628

scook@thecmafoundation.org

